Fluvoxamine and Amantadine: Central Nervous System Acting Drugs Repositioned for COVID-19 as Early Intervention.
Curr Neuropharmacol
; 20(4): 777-781, 2022.
Article
in English
| MEDLINE | ID: covidwho-1785246
ABSTRACT
BACKGROUND:
As the World faces unprecedented pandemic caused by SARS-CoV-2 virus, repositioning of existing drugs to treatment of COVID-19 disease is urgently awaited, provided that high quality scientific evidence supporting safety and efficacy in this new indication is gathered. Efforts concerning drugs repositioning to COVID-19 were mostly focused on antiviral drugs, or drugs targeting the late phase of the disease.METHODS:
Based on published research, the pharmacological activities of fluvoxamine and amantadine, two well-known drugs widely used in clinical practice for psychiatric and neurological diseases, respectively, have been reviewed, with a focus on their potential therapeutic importance in the treatment of COVID-19.RESULTS:
Several preclinical and clinical reports were identified suggesting that these two drugs might exert protective effects in the early phases of COVID-19.CONCLUSION:
Preclinical and early clinical evidence are presented indicating that these drugs hold promise to prevent COVID-19 progression when administered early during the course of infection.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Fluvoxamine
/
COVID-19 Drug Treatment
Type of study:
Experimental Studies
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Curr Neuropharmacol
Year:
2022
Document Type:
Article
Affiliation country:
1570159x19666210729123734
Similar
MEDLINE
...
LILACS
LIS